Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.69 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355585 | 1.00 | CALCRL (0.69) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL3358851 | 0.99 | CALCRL (0.70) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL3358859 | 0.99 | CALCRL (0.70) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL3354233 | 0.96 | CALCRL (0.69) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL3354228 | 0.96 | CALCRL (0.69) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL3349009 | 0.95 | CALCRL (0.66) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL3356221 | 0.95 | CALCRL (0.70) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL3356213 | 0.95 | CALCRL (0.70) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL3382486 | 0.95 | CALCRL (0.75) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL3354131 | 0.95 | CALCRL (0.77) | CALCRLRAMP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696195-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7696195-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7696195-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 101/4885CYP3A4 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.